1[1]Elizabeth M W,Woodhouse A,Mather L E,et al.Morphine pharmacolineti cs after pulmonery administration from a novel aesosol delivery system[J].Clin pharmcol,1997,63:596
3[3]Hochhaus G,Helmut M,Derendorf H,et al .Pharmacokinetic/pharmacodynamic as pects of aerosol therapy using glucocorticoids as a model[J].J Clin Pharmacol ,1997,37:881
4[4]Johnson M,Pharmcodynamics and pharmacokinetics of inhaled glucocorticoids. [J]. J Allergy Immunol.1996，97:169
5[5]Wasserfallen J B,Baraniuk.Clinical use of inhaled corticosteroids in asthm a[J].J Allergy Clin.Immunol 1996,97:177
6[6]Suarez S,Rcardo GR,Schreier ,et al.Effect of dose and release rate on pulm onary targeting of liposomal triamcinolone acetonide phsphate[J].Pharm Res 199 8,15(30):461
7[7]Ricardo J,Gonzalez－Rothi,Suarez S, et al.Pulmonary targeting of liposomal triamcinolone acetonide phosphate[J].Pharm Res.1996,13(11):1699
8[8]Akira Y,Shinji U ,Shozo M.Aborption enhancement of intrapulmonary administe red insulin various absorption enhancers and protease inhib itors in rats[J].J pharm pharcol 1994,46:14
9[9]Yuping L,Ashim K M Effects of phospholipid chain length concertration,char ge ,and vesicle size on pulmonary insulin absorption[J]. Pharm Res 1996,16:76
10[10]Shinzo K,Shuji K,Kazuhiko J.Pulmonary delivery of salmon calcitonin dry po wders containing absorption enhancers in rats[J].Pharm Res ,1996,13(1):80
